Literature DB >> 26643848

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.

Mark Voskoboynik1,2, Victoria Mar2,3,4, Sonia Mailer1, Andrew Colebatch1, Anne Fennessy1, Aleksandra Logan1, Chelsee Hewitt1, Jonathon Cebon5, John Kelly2, Grant McArthur1,6.   

Abstract

BRAF mutations at codons L597 and K601 occur uncommonly in melanoma. Clinical and pathological associations of these mutations were investigated in a cohort of 1119 patients with known BRAF mutation status. A BRAF mutation was identified in 435 patients; Mutations at L597 and the K601E mutation were seen in 3.4 and 3.2% of these, respectively. K601E melanomas tended to occur in male patients, a median age of 58 yr, were generally found on the trunk (64%) and uncommonly associated with chronically sun-damaged (CSD) skin. BRAF L597 melanomas occurred in older patients (median 66 yr), but were associated with CSD skin (extremities or head and neck location - 73.3%, P = 0.001). Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively). Overall, these mutations represent a significant minority of BRAF mutations, but have distinct clinicopathological phenotypes and clinical behaviors.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRAF K601E; BRAF L597; BRAF mutation; primary melanoma

Mesh:

Substances:

Year:  2016        PMID: 26643848     DOI: 10.1111/pcmr.12450

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  8 in total

1.  Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Authors:  Adam A Friedman; Yun Xia; Lorenzo Trippa; Long Phi Le; Vivien Igras; Dennie T Frederick; Jennifer A Wargo; Kenneth K Tanabe; Donald P Lawrence; Donna S Neuberg; Keith T Flaherty; David E Fisher
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

2.  Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Authors:  Nikki R Adler; Rory Wolfe; John W Kelly; Andrew Haydon; Grant A McArthur; Catriona A McLean; Victoria J Mar
Journal:  Br J Cancer       Date:  2017-08-08       Impact factor: 7.640

3.  Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.

Authors:  Markus V Heppt; Timo Siepmann; Jutta Engel; Gabriele Schubert-Fritschle; Renate Eckel; Laura Mirlach; Thomas Kirchner; Andreas Jung; Anja Gesierich; Thomas Ruzicka; Michael J Flaig; Carola Berking
Journal:  BMC Cancer       Date:  2017-08-10       Impact factor: 4.430

4.  Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients.

Authors:  Elodie Long-Mira; Marius Ilie; Emmanuel Chamorey; Florence Leduff-Blanc; Henri Montaudié; Virginie Tanga; Maryline Allégra; Virginie Lespinet-Fabre; Olivier Bordone; Christelle Bonnetaud; Renaud Schiappa; Catherine Butori; Coraline Bence; Jean-Philippe Lacour; Véronique Hofman; Paul Hofman
Journal:  Oncotarget       Date:  2018-11-16

5.  Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation.

Authors:  Fedor V Moiseyenko; Vitaliy V Egorenkov; Mikhail M Kramchaninov; Elizaveta V Artemieva; Svetlana N Aleksakhina; Maxim M Holmatov; Vladimir M Moiseyenko; Evgeny N Imyanitov
Journal:  Case Rep Oncol       Date:  2019-05-16

6.  Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.

Authors:  Tianli Cheng; Zhongping Gu; Danni Song; Sisi Liu; Xiaoling Tong; Xue Wu; Zhifeng Lin; Wei Hong
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

Review 7.  Targeted Therapy for Melanomas Without BRAF V600 Mutations.

Authors:  Christian Menzer; Jessica C Hassel
Journal:  Curr Treat Options Oncol       Date:  2022-04-05

8.  Acetylation-dependent regulation of BRAF oncogenic function.

Authors:  Xiangpeng Dai; Xiaoling Zhang; Qing Yin; Jia Hu; Jianping Guo; Yang Gao; Aidan H Snell; Hiroyuki Inuzuka; Lixin Wan; Wenyi Wei
Journal:  Cell Rep       Date:  2022-01-18       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.